Skip to main content

Advertisement

SpringerLink
Log in

Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update

  • Evidence-Based Medicine (L. Roever, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This clinical update is intended to focus in relationship between HIV infection and use of antiretroviral therapy (ART) and statin.

Recent Findings

Though ART significantly changed the course of HIV infection, it is related to numerous side effects principally to the lipid profile. In this way, statins became one of the most used lipid-lowering therapies in this population. In our clinical update, we evaluated studies that demonstrate the relationship and molecular mechanisms that HIV infection and ART use trigger dyslipidemia and also the use of statin to reduce this condition.

Summary

We have demonstrated that use of statin can be used in dyslipidemic HIV-infected people as long as there is no drug interaction with ART. Recently, studies using rosuvastatin have shown greater effects when compared to the other statins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Malta M, da Silva CM, Magnanini MM, et al. Improvement of HAART in Brazil, 1998–2008: a nationwide assessment of survival times after AIDS diagnosis among men who have sex with men. BMC Public Health. 2015;15:1530. This study shows the improvement of ART in HIV infection.

    Article  Google Scholar 

  2. Venturini A, Giannini B, Montefiori M, di Biagio A, Mazzarello G, Cenderello G, et al. Quality of life of people living with HIV, preliminary results from IANUA (Investigation on Antiretroviral Therapy) study. J Int AIDS Soc. 2014;17(4 Suppl 3):19581. https://doi.org/10.7448/IAS.17.4.19581.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chanu B, Valensi P. Lipid disorders in patients with HIV-induced diseases. Presse Med. 2005;34(15):1087–94. https://doi.org/10.1016/S0755-4982(05)84124-7.

    Article  CAS  PubMed  Google Scholar 

  4. • Munger AM, Chow DC, Playford MP, Parikh NI, Gangcuangco LMA, Nakamoto BK, et al. Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens. AIDS Res Hum Retrovir. 2015;31(2):221–8. The study characterizes the lipid profile among HIV-infected people. https://doi.org/10.1089/aid.2014.0239.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Parakh A, Dubey AP, Kumar A, Maheshwari A. Lipodystrophy and metabolic complications of highly active antiretroviral therapy. Indian J Pediatr. 2009;76(10):1017–21. https://doi.org/10.1007/s12098-009-0216-9.

    Article  PubMed  Google Scholar 

  6. Group DADS, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35.

    Article  Google Scholar 

  7. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003. https://doi.org/10.1056/NEJMoa030218.

    Article  PubMed  Google Scholar 

  8. •• Esser S, Eisele L, Schwarz B, Schulze C, Holzendorf V, Brockmeyer NH, et al. Rates of cardiovascular events and deaths are associated with advanced stages of HIV-infection: results of the HIV HEART study 7, 5 year follow-up. J Int AIDS Soc. 2014;17(4 Suppl 3):19542. The article demonstrated the development of cardiovascular disease in HIV-infected people. https://doi.org/10.7448/IAS.17.4.19542.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kuller LH, Tracy R, Belloso W, Wit SD, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. https://doi.org/10.1371/journal.pmed.0050203.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Rajasuriar R, Khoury G, Kamarulzaman A, French MA, Cameron PU, Lewin SR. Persistent immune activation in chronic HIV infection: do any interventions work? AIDS. 2013;27(8):1199–208. https://doi.org/10.1097/QAD.0b013e32835ecb8b.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Falcao MC, Zirpoli JC, Albuquerque VM, et al. Association of biomarkers with atherosclerosis and risk for coronary artery disease in patients with HIV. Arq Bras Cardiol. 2012;99:971–8.

    Article  CAS  PubMed  Google Scholar 

  12. Gleeson M. Immune function in sport and exercise. J Appl Physiol. 2007;103(2):693–9. https://doi.org/10.1152/japplphysiol.00008.2007.

    Article  CAS  PubMed  Google Scholar 

  13. Shikuma CM, Gangcuangco LM, Killebrew DA, et al. The role of HIV and monocytes/macrophages in adipose tissue biology. J Acquir Immune Defic Syndr. 2014;65(2):151–9. https://doi.org/10.1097/01.qai.0000435599.27727.6c.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Esser S, Gelbrich G, Brockmeyer N, Goehler A, Schadendorf D, Erbel R, et al. Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clin Res Cardiol. 2013;102(3):203–13. https://doi.org/10.1007/s00392-012-0519-0.

    Article  PubMed  Google Scholar 

  15. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13(8):453–68. https://doi.org/10.1111/j.1468-1293.2012.00996.x.

    CAS  PubMed  Google Scholar 

  16. Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014;35(21):1373–81. https://doi.org/10.1093/eurheartj/eht528.

    Article  CAS  PubMed  Google Scholar 

  17. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34. https://doi.org/10.1097/01.qai.0000233310.90484.16.

    Article  CAS  PubMed  Google Scholar 

  18. Tiwari A, Bansal V, Chugh A, Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf. 2006;5(5):651–66. https://doi.org/10.1517/14740338.5.5.651.

    Article  CAS  PubMed  Google Scholar 

  19. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58(23):2432–46. https://doi.org/10.1016/j.jacc.2011.10.824.

    Article  PubMed  Google Scholar 

  20. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. https://doi.org/10.1016/S0140-6736(05)67394-1.

    Article  CAS  PubMed  Google Scholar 

  21. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.

    Article  Google Scholar 

  22. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–8. https://doi.org/10.1001/jama.285.13.1711.

    Article  CAS  PubMed  Google Scholar 

  23. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–60. https://doi.org/10.1016/S0002-9149(03)00530-7.

    Article  CAS  PubMed  Google Scholar 

  24. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58. https://doi.org/10.1016/S0140-6736(03)12948-0.

    Article  CAS  PubMed  Google Scholar 

  25. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504. https://doi.org/10.1056/NEJMoa040583.

    Article  CAS  PubMed  Google Scholar 

  26. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson Å, McMurray JV, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005;7(6):1059–69. https://doi.org/10.1016/j.ejheart.2005.09.005.

    Article  CAS  PubMed  Google Scholar 

  27. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6(5):635–41. https://doi.org/10.1016/j.ejheart.2004.03.001.

    Article  CAS  PubMed  Google Scholar 

  28. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–74.

    Article  Google Scholar 

  29. Ito MK, Talbert RL, Tsimikas S. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy. 2006;26(7part2):85S–97S; discussion 8S–101S; quiz 6S–8S. https://doi.org/10.1592/phco.26.7part2.85S.

    Article  CAS  PubMed  Google Scholar 

  30. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37–44. https://doi.org/10.1016/j.molmed.2007.11.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zeiser R, Maas K, Youssef S, Durr C, Steinman L, Negrin RS. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology. 2009;127(1):18–25. https://doi.org/10.1111/j.1365-2567.2008.03011.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003;5(5):372–8. https://doi.org/10.1007/s11883-003-0008-z.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45(1):89–118. https://doi.org/10.1146/annurev.pharmtox.45.120403.095748.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Zhou Q, Liao JK. Pleiotropic effects of statins—basic research and clinical perspectives. Circ J. 2010;74(5):818–26. https://doi.org/10.1253/circj.CJ-10-0110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858–68. https://doi.org/10.7326/0003-4819-150-12-200906160-00009.

    Article  PubMed  Google Scholar 

  36. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc DrugsTher. 2005;19(6):403–14. https://doi.org/10.1007/s10557-005-5686-z.

    CAS  Google Scholar 

  37. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. https://doi.org/10.1016/j.jacl.2012.03.003.

    Article  PubMed  Google Scholar 

  38. Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med. 2010;362(6):564–5. https://doi.org/10.1056/NEJMc0908215.

    Article  PubMed  Google Scholar 

  39. Cohen DE, Anania FA, Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert P. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(8A):77C–81C. https://doi.org/10.1016/j.amjcard.2005.12.014.

    Article  CAS  PubMed  Google Scholar 

  40. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924–9. https://doi.org/10.2337/dc09-0738.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. •• Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131–49. This meta analysis shows an important data of side effects of statin use. https://doi.org/10.1002/pds.4020.

    Article  CAS  PubMed  Google Scholar 

  42. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289(22):2978–82. https://doi.org/10.1001/jama.289.22.2978.

    Article  CAS  PubMed  Google Scholar 

  43. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother. 2008;61(2):238–45. https://doi.org/10.1093/jac/dkm475.

    Article  CAS  PubMed  Google Scholar 

  44. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(1):10–4. https://doi.org/10.1093/jac/dkh013.

    Article  CAS  PubMed  Google Scholar 

  45. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351(9119):1881–3. https://doi.org/10.1016/S0140-6736(98)03391-1.

    Article  CAS  PubMed  Google Scholar 

  46. D'Ascenzo F, Agostoni P, Abbate A, Castagno D, Lipinski MJ, Vetrovec GW, et al. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis. 2013;226(1):178–85. https://doi.org/10.1016/j.atherosclerosis.2012.10.065.

    Article  PubMed  Google Scholar 

  47. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy. 2000;20(9):1066–71. https://doi.org/10.1592/phco.20.13.1066.35033.

    Article  CAS  PubMed  Google Scholar 

  48. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6(7):e21843. https://doi.org/10.1371/journal.pone.0021843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Causevic-Ramosevac A, Semiz S. Drug interactions with statins. Acta Pharma. 2013;63(3):277–93. https://doi.org/10.2478/acph-2013-0022.

    Article  CAS  Google Scholar 

  50. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52(10):815–31. https://doi.org/10.1007/s40262-013-0075-4.

    Article  CAS  PubMed  Google Scholar 

  51. Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004;147:E18.

    PubMed  Google Scholar 

  52. Hurlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart. 2006;92(1):110–2. https://doi.org/10.1136/hrt.2004.056523.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Mallon PW, Miller J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men—a randomized, placebo-controlled study. AIDS. 2006;20(7):1003–10. https://doi.org/10.1097/01.aids.0000222072.37749.5a.

    Article  CAS  PubMed  Google Scholar 

  54. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res. 2008;6(6):572–8. https://doi.org/10.2174/157016208786501481.

    Article  CAS  PubMed  Google Scholar 

  55. Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24(1):77–83. https://doi.org/10.1097/QAD.0b013e328331d2ab.

    Article  CAS  PubMed  Google Scholar 

  56. Calza L, Trapani F, Bartoletti M, Manfredi R, Colangeli V, Borderi M, et al. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials. 2012;13(3):153–61. https://doi.org/10.1310/hct1303-153.

    Article  CAS  PubMed  Google Scholar 

  57. • Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209(8):1156–64. The article demonstrates the pleiotropic effects of statin in HIV people. https://doi.org/10.1093/infdis/jiu012.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis. 2014;59(8):1148–56. https://doi.org/10.1093/cid/ciu523.

    Article  PubMed  PubMed Central  Google Scholar 

  59. •• Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, Calcagno A, Cannillo M, et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J. 2016. A very good review on effects of statin in HIV patients.;37(48):3600–9. https://doi.org/10.1093/eurheartj/ehv734.

    Article  PubMed  Google Scholar 

  60. •• Lichtenstein KA, Hart RL, Wood KC, Bozzette S, Buchacz K, Brooks JT, et al. Statin use is associated with incident diabetes mellitus among patients in the HIV outpatient study. J Acquir Immune Defic Syndr. 2015;69(3):306–11. The article demonstrates the association between the use of statin and incidence of diabetes. https://doi.org/10.1097/QAI.0000000000000581.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Master Institute of Education President Antônio Carlos, Avenida Minas Gerais, 1889 – Centro, Araguari, MG, 38.440-046, Brazil

    Hugo Ribeiro Zanetti & Alexandre Gonçalves

  2. Department of Clinical Research, Federal University of Uberlândia, Uberlândia, MG, Brazil

    Hugo Ribeiro Zanetti, Leonardo Roever, Alexandre Gonçalves & Elmiro Santos Resende

  3. Paulista University, Brasília, DF, Brazil

    Alexandre Gonçalves

  4. Atenas College, Paracatu, MG, Brazil

    Alexandre Gonçalves

Authors
  1. Hugo Ribeiro Zanetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonardo Roever
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexandre Gonçalves
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elmiro Santos Resende
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hugo Ribeiro Zanetti.

Ethics declarations

Conflict of Interest

Hugo Ribeiro Zanetti, Leonardo Roever, Alexandre Gonçalves, and Elmiro Santos Resende declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Evidence-Based Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zanetti, H.R., Roever, L., Gonçalves, A. et al. Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update. Curr Atheroscler Rep 20, 9 (2018). https://doi.org/10.1007/s11883-018-0708-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-018-0708-z

Keywords

Search

Navigation